Ionis Pharmaceuticals (IONS) Capital Expenditures (2009 - 2026)

Ionis Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 73.04% year-over-year to $21.8 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 81.89% decrease from a year earlier, with the FY2025 full-year figure at $478000.0, down 98.94% from the prior year.
• Capital Expenditures grew to $21.8 million in Q1 2026 per IONS's latest filing, from -$29.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $25.5 million in Q4 2024 and bottomed at -$29.7 million in Q4 2025.
• The 5-year median for Capital Expenditures is $5.5 million (2022), against an average of $6.3 million.
• Across the five-year window, Capital Expenditures surged 3213.19% in 2024 and tumbled 216.38% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $4.1 million in 2022, then slumped by 119.79% to -$819000.0 in 2023, then jumped by 3213.19% to $25.5 million in 2024, then tumbled by 216.38% to -$29.7 million in 2025, then jumped by 173.34% to $21.8 million in 2026.
• Per Business Quant, the three latest IONS Capital Expenditures figures stand at $21.8 million (Q1 2026), -$29.7 million (Q4 2025), and $5.3 million (Q3 2025).